Lyell Immunopharma (LYEL) Return on Sales [ROS] (2020 - 2026)
Lyell Immunopharma's Return on Sales [ROS] came in at -1183425.00% for Q2 2026, down 594175.00 percentage points from -589250.00% a year earlier but up 1029625.00 percentage points from the prior quarter.
Lyell Immunopharma (LYEL) Return on Sales [ROS] (2020 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Lyell Immunopharma reported Return on Sales [ROS] of -949981.48%, down 356383.15 percentage points year-over-year; for FY2025, it was -748344.44%, down 160221.49 percentage points from FY2024.
- Return on Sales [ROS] has declined in each of the last three years, with a five-year change of -745611.89 percentage points (FY2020 to FY2025).
- Going back by year, Return on Sales [ROS] was -588122.95% in FY2024 (-398116.80 pp), -190006.15% in FY2023 (-189785.26 pp), -220.89% in FY2022 (+1795.78 pp) and -2016.68% in FY2021 (+715.88 pp).
- The five-year range for quarterly Return on Sales [ROS] is -2214566.67% (Q3 2022) to -30.55% (Q4 2022).
- Year-over-year, Return on Sales [ROS] has declined for five consecutive quarters, with an average year-over-year change of -353681.16 percentage points over the last eight quarters.
- The fastest year-over-year change in Return on Sales [ROS] over five years came in Q3 2023 (a gain of 1978410.67 percentage points), and the weakest in Q3 2022 (a drop of 2212782.24 percentage points).
- Business Quant data shows LYEL's Return on Sales [ROS] at -2213050.00% (Q1 2026), -2127400.00% (Q4 2025) and -248353.33% (Q3 2025) in the three quarters before Q2 2026.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 51.16% |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 28.21% |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 37.86% |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | -3.52% |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 32.97% |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 20.57% |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 34.95% |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | -133.21% |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 28.37% |
| 10 | Lyell Immunopharma | 216.66 Mn | 216.66 Mn | - | -1,183,425.00% |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,183,425.00% |
| Mar 31, 2026 | -2,213,050.00% |
| Dec 31, 2025 | -2,127,400.00% |
| Sep 30, 2025 | -248,353.33% |
| Jun 30, 2025 | -589,250.00% |
| Mar 31, 2025 | -819,528.57% |
| Dec 31, 2024 | -1,828,609.09% |
| Sep 30, 2024 | -148,544.12% |
| Jun 30, 2024 | -396,369.23% |
| Mar 31, 2024 | -1,852,500.00% |
| Dec 31, 2023 | -457,753.85% |
| Sep 30, 2023 | -236,156.00% |
| Jun 30, 2023 | -244,092.59% |
| Mar 31, 2023 | -96,240.00% |
| Dec 31, 2022 | -30.55% |
| Sep 30, 2022 | -2,214,566.67% |
| Jun 30, 2022 | -104.25% |
| Mar 31, 2022 | -12,400.72% |
| Dec 31, 2021 | -1,684.55% |
| Sep 30, 2021 | -1,784.43% |
Lyell Immunopharma Return on Sales [ROS] API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LYEL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "return-on-sales-[ros]", "ticker": "LYEL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=LYEL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();